Drug Trial Radar · NCT04455243
Inflammatory Regulation Effect of NAC on COVID-19 Treatment
Last checked: Nov 20, 2026Latest source record: Jul 21, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
1,180
Planned (sponsor's estimate)
Start
Aug 1, 2020
Primary completion
Aug 30, 2021
Study completion Aug 30, 2021
Sponsor
- Lead sponsor
- Dr. Tariq AlhawassiAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jul 2, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Study times to evaluate the efficacy of N-Acetylcysteine therapy in the management of adult admitted patients with COVID-19.
Conditions
- COVID-19
Interventions
N-Acetyl cysteineDrug
150 mg/kg every 12 hours for 14 days (oral/IV) Diluted in 200 ml diluent (D5%, NS)
PlaceboDrug
Matching placebo administered in the same schedule and volume as NAC
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to RecoveryTime frame: 28 days
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.